Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline

Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best stocks under $25 to buy now. Following the company’s analyst meeting on December 11, Leerink Partners boosted its price target for Roivant Sciences Ltd. (NASDAQ:ROIV) to $32 from $29, keeping an Outperform rating on the company’s shares. The firm highlighted lower estimated operational expenses in the years ahead than previously modeled, resulting in reduced expected losses and significant profitability beginning in fiscal year 2029. By the end of ...